


Driving R&D Towards Global Public Health and Health Equity: RIGHT Foundation's Approach

Hoon Sang Lee, MD, MPH, PhD
CSO, RIGHT Foundation

9 July 2025

RIGHT foundation: Korea's first non-profit organization dedicated to funding global health R&D

- Established in 2018 with the intent to engage Korean life science partners to develop and make available critical health technologies as global public good
- Public private partnership with the Korean Ministry of Health and Welfare (MOHW), Bill & Melinda Gates Foundation and Korean life science industry
- Leverages the Korean Ministry of Health and Welfare's Official Development Assistance



Gates Foundation



Our Vision, Mission & Objectives

Vision:

A world where infectious diseases pose no threat to any community

Mission: Alleviate the burden of infectious diseases that disproportionately affect the people in low- and middle-income countries (LMICs)

Strategic Objectives & Funding Programs	PRODUCT DEVELOPMENT AWARD	EVIDENCE GENERATION AWARD	TRAINING AWARD
	Develop essential health technologies as global public goods (e.g. public procurement, global access, technology transfer)	<ul style="list-style-type: none"> Fill critical knowledge gaps to further the impact of product development (e.g. support licensure, policy development or public procurement) 	Train work force in manufacturing essential health technologies (e.g. regional-level self-sufficiency in vaccine manufacturing)
Core Value	<p style="text-align: center;">COLLABORATION</p> <ul style="list-style-type: none"> Foster an exchange of knowledge and skills (i.e. co-develop) Contribute Korea's strengths in engineering, process optimization, manufacturing 		

RIGHT's Funding Programs

	Product Development Award	Evidence Generation Award	Training Award
Objectives	<ul style="list-style-type: none"> Develop essential medical countermeasures as global public goods 	<ul style="list-style-type: none"> Fill critical knowledge gaps to further the impact of product development (e.g. support licensure, policy development or public procurement) 	<ul style="list-style-type: none"> Train work force in manufacturing essential medical countermeasures
Development Stage	<ul style="list-style-type: none"> From pre-clinical development at/near IND-enabling studies throughout clinical development to regulatory approval and/or WHO prequalification Access Enabling Research Technology Transfer 	<ul style="list-style-type: none"> n/a 	<ul style="list-style-type: none"> Basics for biopharmaceuticals and bioprocessing Vaccine manufacturing bioprocessing Regulatory process for biopharmaceuticals
Product Types	vaccines, therapeutics/biologics, diagnostics		vaccines
Requirements	<ul style="list-style-type: none"> At least one Korean partner, 50% co-funding if the project team consists of a commercial partner 	<ul style="list-style-type: none"> Local institutions from the countries that the proposed activities focus on 	<ul style="list-style-type: none"> Individuals from LMICs holding positions related to vaccine manufacturing
Funding Amount & Duration	<ul style="list-style-type: none"> Up to 4 billion KRW/project (approximately 3.4M USD) for 3 years 	<ul style="list-style-type: none"> Up to 200 million KRW/ project (approximately 165,000 USD, 1 yr) 	<ul style="list-style-type: none"> 3-week on-line and 5-week hands-on training in Korea including travel expenses and accommodation
Investment Criteria	<ol style="list-style-type: none"> Infectious diseases with a disproportionate burden in LMICs Unmet medical needs for new or improved health products Insufficient commercial incentives to drive R&D innovation Opportunity to contribute Korea's strengths in R&D 		

Driving R&D to serve global and regional public health : what it means and what it does not mean

Key Considerations:


- Design with **global access** in mind from the start (e.g. context, target use-case, product characteristics, end-user requirements)
- Plan for integration into the **local public health system**
- Develop **market access strategies** early (private AND public market)
- Engage the **key stakeholders** early (e.g. end-users, local governments, regulatory authorities, global procuring agencies)
- Seeks innovation outside the “first-in-class” paradigm to achieve global access (ie. optimize manufacturing process, improve thermostability, improve ease of operation/implementation)
- Global health R&D should NOT mean charity




Baboucarr Sarr, community health nurse and midwife, talking to a young mother at an outreach immunisation session in Nioro-Jataba, The Gambia. Credit: Gavi/2018/Guido Dingemans

Funding committed across award and product type


By Award Type



By Product Type



Funding committed across disease type



1) **Pneumonia**: Meningitis + Neonatal Sepsis; 2) **EDD**: Enteric and Diarrheal diseases + Cholera + Hep A + Rotavirus + Typhoid; 3) **NTD**: Neglected Tropical Diseases, Chikungunya + Dengue + Leishmaniasis + Schistosomiasis + Onchocerciasis; 4) **Combined**: Hexa, Penta, Measles-Rubella, Multiple infectious diseases; 5) **STIs/AMR**: Sexually transmitted infections + antimicrobial resistance; 6) **Pandemic potential**, COVID19 + Influenza; 7) **GAS**: Group A Streptococcus; 8) **Others**: 4 EGAs and 1 TA not specific to diseases; 9) **SFTS**: Severe fever with thrombocytopenia syndrome


Currently Active Grants: RiGHT aims for an impact-driven, risk-balanced portfolio

Vaccines
Total 8
25.3 million
USD

Therapeutics
Total 5
12.9 million
USD

Diagnostics
Total 9
19.0 million
USD

Total 22 grants
Total Committed Funding by RiGHT: 57.2 million USD
Total Project Costs: 156.0 million USD



*POCT: Point-of-Care molecular diagnostic test

What does success look like for RIGHT?



STANDARD G6PD



- First quantitative rapid diagnostic test to detect Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Policy recommendation by Brazil to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing *P.vivax* malaria.
- Introduced in Cambodia, Laos, and Vietnam for routine test use with primaquine (the standard treatment for *P. vivax*).
- Currently, registered in 18 malaria endemic countries

<https://medaccess.org/our-agreements/agreements/g6pd-testing/>

Impact to date	9,000	20,300	\$369,000
By the end of 2023:	<i>additional people on any treatment</i>	<i>malaria relapses averted</i>	<i>savings for procurers</i>

What does success look like for RIGHT? miLabMAL Platform





Microscopic Test



VS

miLab



<p>SLOW 20-90 min.</p>		<p>FAST 15-25 min.</p>
<p>TEDIOUS 8 steps</p>		<p>SIMPLE 3 steps</p>
<p>15 types of material & reagents</p>		<p>ONE Cartridge</p>
<p>Sink Water supply Sewage Liquid Waste Ventilation</p>		<p>NO Infrastructure</p>

- an AI-powered malaria diagnostic platform with a fully automated process from sample preparation (including smearing and staining) to data analysis
- Fully automated sample preparation, including smearing and staining
- Licensure by CE/IVDR, TFDA, FDA & MHRA
- Successful field evaluation study by National Institute of Public Health (INSP) of Côte d'Ivoire
- Agreement with the Government of Benin for large-scale public procurement to deliver at least 219 miLab™ units over three years
- Further application potential for diagnosis of cervical cancer being explored

RIGHT project partners

International

TOTAL

22

Countries

Of which

LMIC

12

Countries

TOTAL

46

Institutions

Of which

LMIC

20

Institutions

Korean

TOTAL

64

Institutions

Acknowledgement



Gates Foundation

Full Partner				
Associate Partner				

